Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma

J Clin Oncol. 2012 Nov 20;30(33):4168-70. doi: 10.1200/JCO.2012.44.0347. Epub 2012 Sep 10.
No abstract available

Publication types

  • Comment

MeSH terms

  • Bridged-Ring Compounds / administration & dosage*
  • Bridged-Ring Compounds / adverse effects*
  • Female
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors*
  • Lymphoma / drug therapy*
  • Lymphoma / enzymology*
  • Male
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrimidines / administration & dosage*
  • Pyrimidines / adverse effects*

Substances

  • 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
  • Bridged-Ring Compounds
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Janus Kinase 2